Results 181 to 190 of about 74,688 (254)

Synergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for relapsed/refractory peripheral T cell lymphoma. [PDF]

Front Immunol
Huang L, Guo H, Teng Y, Pang D, Zhang F, Sun Y, Ong CK, Tan J, Li W.   +8 more
europepmc   +1 more source

AGO Recommendations for Diagnosis and Treatment of Patients with Early and Metastatic Breast Cancer: Update 2012 [PDF]

, 2011
Harbeck, Nadia, Scharl, Anton, Thomssen, Christoph   +2 more
core   +2 more sources

Vascular Response Occurring at 3 Months After Everolimus-Eluting Cobalt–Chromium Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction vs. Stable Coronary Artery Disease

, 2020
Masaru Ishida, Daisuke Terashita, Tomonori Itoh, Hiromasa Otake, Yoshiro Tsukiyama, Tatsuo Kikuchi, Takatoshi Hayashi, Takahide Suzuki, Yoshiaki Ito, Takashi Morita, Kiyoshi Hibi, Takahiro Sawada, Takayuki Okamura, Junya Shite, Fumiaki Takahashi, Toshiro Shinke, Yoshihiro Morino   +16 more
openalex   +2 more sources

Molecular guided therapy leading to exceptional response in relapsed osteosarcoma. [PDF]

Front Pharmacol
Wert E, Menachery L, Hengst J, Arjmandi T, Nagulapally AB, Gandra D, Brown V, Sholler GS, Dandekar S.   +8 more
europepmc   +1 more source

Effect of early everolimus-facilitated reduction of acrolimus on efficacy and renal function in de novo liver transplant recipients: 24-month results for the North American subpopulation [PDF]

, 2017
Chapman, William C, et al,
core   +1 more source

Everolimus with reduced tacrolimus versus standard tacrolimus in living-donor liver transplant recipients: Baseline data from the H2307 Study

, 2015
Sumana Ramachandra, Arvinder S. Soin, Roman Kolar, Gary Levy, Long‐Bin Jeng, S.G. Lee, W.C. Lee, Dong Jin Joo, Jaime Sanchez, C. Sips, Jossy Kochuparampil, N. Ugile   +11 more
openalex   +1 more source

Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma [PDF]

, 2012
H-S. Shiah, Cheng‐Yu Chen, Chia‐Yen Dai, Chin‐Fu Hsiao, Yenn‐Jiang Lin, Wu‐Chou Su, Ji Yoon Chang, Jacqueline Whang‐Peng, P. W. Lin, Jian Huang, Lin-Qing Chen   +10 more
openalex   +1 more source

Everolimus-exemestane (EE) vs palbociclib-letrozole (PL) or palbociclib-fulvestrant (PF) in the treatment of metastatic HR+, HER2- breast cancer. Indirect comparisons with network meta-analysis for daily clinical practice [PDF]

, 2017
Lucia Stocchi, Luca Gianni, Mario Nicolini, Carlotta Santelmo, Ornella Carminati, Valentina Arcangeli, Maximilian Papi, Chiara Cherubini, A. Polselli, Davide Tassinari   +9 more
openalex   +1 more source

System analysis links SMARCD3 regulons to growth signaling and MEK inhibitor response in everolimus-resistant ER+ breast cancer cells. [PDF]

Cell Rep Med
Medina EF, Farmaki E, Griffiths JI, Bild AH, Nath A.   +4 more
europepmc   +1 more source

Everolimus-Induced Pulmonary Toxicity in a Lung Transplant Recipient: A Case Report. [PDF]

Cureus
Varón-Vega F, Martinez-Ayala MC, Rodríguez C, Mendoza D, Tellez LJ, Tuta-Quintero E.   +5 more
europepmc   +1 more source